NASDAQ:PMDPsychemedics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Psychemedics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $5.79 -0.26 (-4.30 %) (As of 07/3/2020 04:00 PM ET) Add Compare Share Today's Range$5.70Now: $5.79▼$6.1550-Day Range$4.90MA: $5.52▼$6.0552-Week Range$4.54Now: $5.79▼$10.69Volume28,030 shsAverage Volume26,335 shsMarket Capitalization$32.02 millionP/E Ratio41.36Dividend Yield12.44%Beta0.85 ProfileAdvanced ChartCompetitorsDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Psychemedics Corporation provides testing services for the detection of drugs of abuse through the analysis of hair samples in the United States and internationally. The company's tests provide quantitative information that can indicate the approximate amount of drug ingested, as well as historical data, which can show a pattern of individual drug use over a longer period of time. It provides screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, PCP, amphetamines, synthetic cannabinoids, and benzodiazepines, as well as opiates, including heroin, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine. The company offers its services to employers for applicant and employee testing; treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children's drug use; and Fortune 500 companies and small to mid-size corporations, as well as school and government entities. Psychemedics Corporation was founded in 1985 and is headquartered in Acton, Massachusetts.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Psychemedics. Previous Next 3.0 Community Rank Outperform VotesPsychemedics has received 142 “outperform” votes. (Add your “outperform” vote.)Underperform VotesPsychemedics has received 93 “underperform” votes. (Add your “underperform” vote.)Community SentimentPsychemedics has received 60.43% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Psychemedics and other stocks. Vote “Outperform” if you believe PMD will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PMD will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 1.7 Dividend Strength Dividend LeadershipPsychemedics is a leading dividend payer. It pays a dividend yield of 12.44%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthPsychemedics has only been increasing its dividend for 2 years. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Psychemedics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 13.30% of the stock of Psychemedics is held by insiders.Percentage Held by Institutions47.58% of the stock of Psychemedics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Psychemedics is 41.36, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 15.41.Price to Earnings Ratio vs. SectorThe P/E ratio of Psychemedics is 41.36, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 17.08.Price to Book Value per Share RatioPsychemedics has a P/B Ratio of 1.90. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 3.0Dividend Strength: 1.7Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.13 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Medical laboratories Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PMD Previous Symbol CUSIPN/A CIK806517 Webwww.psychemedics.com Phone978-206-8220Debt Debt-to-Equity Ratio0.11 Current Ratio2.19 Quick Ratio2.19Price-To-Earnings Trailing P/E Ratio41.36 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$37.68 million Price / Sales0.85 Cash Flow$0.97 per share Price / Cash Flow5.99 Book Value$3.05 per share Price / Book1.90Profitability EPS (Most Recent Fiscal Year)N/A Net Income$1.54 million Net Margins2.14% Return on Equity9.48% Return on Assets6.26%Miscellaneous Employees250 Outstanding Shares5,530,000Market Cap$32.02 million Next Earnings Date7/28/2020 (Estimated) OptionableNot Optionable NASDAQ:PMD Rates by TradingView Receive PMD News and Ratings via Email Sign-up to receive the latest news and ratings for PMD and its competitors with MarketBeat's FREE daily newsletter. Psychemedics (NASDAQ:PMD) Frequently Asked Questions How has Psychemedics' stock been impacted by COVID-19 (Coronavirus)? Psychemedics' stock was trading at $6.95 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, PMD shares have decreased by 16.7% and is now trading at $5.79. View which stocks have been most impacted by Coronavirus. When is Psychemedics' next earnings date? Psychemedics is scheduled to release its next quarterly earnings announcement on Tuesday, July 28th 2020. View our earnings forecast for Psychemedics. How were Psychemedics' earnings last quarter? Psychemedics Corp. (NASDAQ:PMD) released its quarterly earnings results on Wednesday, May, 13th. The company reported ($0.03) earnings per share (EPS) for the quarter. The company earned $7.54 million during the quarter. Psychemedics had a return on equity of 9.48% and a net margin of 2.14%. View Psychemedics' earnings history. How often does Psychemedics pay dividends? What is the dividend yield for Psychemedics? Psychemedics declared a quarterly dividend on Tuesday, February 11th. Shareholders of record on Friday, February 21st will be given a dividend of $0.18 per share on Tuesday, March 3rd. This represents a $0.72 annualized dividend and a dividend yield of 12.44%. The ex-dividend date of this dividend is Thursday, February 20th. View Psychemedics' dividend history. Has Psychemedics been receiving favorable news coverage? Press coverage about PMD stock has been trending negative this week, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Psychemedics earned a media sentiment score of -2.8 on InfoTrie's scale. They also gave headlines about the company a news buzz of 7.0 out of 10, indicating that recent press coverage is likely to have an impact on the company's share price in the near future. View the latest news about Psychemedics. Who are some of Psychemedics' key competitors? Some companies that are related to Psychemedics include Enzo Biochem (ENZ), Biocept (BIOC), Celcuity (CELC), Anpac Bio-Medical Science (ANPC), Miragen Therapeutics (MGEN), OpGen (OPGN), Avant Diagnostics (AVDX), CBA Florida (CBAI), PotNetwork (POTN), Cancer Genetics (CGIX), First Choice Healthcare Solutions (FCHS) and Aeon Global Health (AGHC). View all competitors. What other stocks do shareholders of Psychemedics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Psychemedics investors own include Ring Energy (REI), Ring Energy (REI), AT&T (T), Zynerba Pharmaceuticals (ZYNE), AbbVie (ABBV), Canopy Growth (CGC), Dominion Energy (D), Pattern Energy Group (PEGI), Athersys (ATHX) and Corbus Pharmaceuticals (CRBP). Who are Psychemedics' key executives? Psychemedics' management team includes the following people: Mr. Raymond C. Kubacki Jr., Chairman, CEO & Pres (Age 74)Mr. Neil Lerner, VP of Fin. & Treasurer (Age 51)Dr. Michael I. Schaffer, VP of Laboratory Operations (Age 74)Dr. Werner A. Baumgartner Ph.D., FounderMs. Annette Baumgartner, Founder What is Psychemedics' stock symbol? Psychemedics trades on the NASDAQ under the ticker symbol "PMD." How do I buy shares of Psychemedics? Shares of PMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Psychemedics' stock price today? One share of PMD stock can currently be purchased for approximately $5.79. How big of a company is Psychemedics? Psychemedics has a market capitalization of $32.02 million and generates $37.68 million in revenue each year. Psychemedics employs 250 workers across the globe. What is Psychemedics' official website? The official website for Psychemedics is www.psychemedics.com. How can I contact Psychemedics? Psychemedics' mailing address is 289 GREAT ROAD Suite 200, ACTON MA, 01720. The company can be reached via phone at 978-206-8220. This page was last updated on 7/4/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
